Certified by Founder
Lodge
Engrail Therapeutics
start up
United States
- San Diego, California
- 20/03/2024
- Series B
- $157,000,000
We are a neuroscience company forging a new direction to reduce the enormous burden of diseases that impact the nervous system. At our core, we unite biological insights with clinically meaningful solutions to build and catalyze a diversified portfolio of transformative medicines. Harnessing our rigorous scientific approach to identify the most promising therapies, we leverage our flexible transaction model to advance assets with validated mechanisms and efficiently move them through development to commercialization.
- Industry Pharmaceutical Manufacturing
- Website https://www.engrail.com/
- LinkedIn https://www.linkedin.com/company/engrail-therapeutics/
Potpie AI | $2,200,000 | (Feb 24, 2026)
Solid (AI for Data) | $20,000,000 | (Feb 24, 2026)
Comeryx | $7,500,000 | (Feb 24, 2026)
Maazah | $2,000,000 | (Feb 24, 2026)
Turgo.ai | $1,000,000 | (Feb 24, 2026)
Sherpas | $3,200,000 | (Feb 24, 2026)
Patientdesk.ai (YC W26) | $1,000,000 | (Feb 24, 2026)
Aalyria | $100,000,000 | (Feb 24, 2026)
Ubicquia, Inc | $106,000,000 | (Feb 24, 2026)
Freeform | $67,000,000 | (Feb 24, 2026)
Coral Care | $13,000,000 | (Feb 24, 2026)
Reload | $2,275,000 | (Feb 24, 2026)